BioNTech and Duality Biologics add third ADC candidate to oncology partnership

09 Aug 2023
·
Deals
www.pmlive.com
Phase 2ImmunotherapyFast TrackLicense out/inAcquisition
BioNTech and Duality Biologics have expanded their existing agreement to include a third antibody-drug conjugate (ADC) for solid tumours.
BioNTechaniesDuality Biologicsrst deal covering two ADCs in April this year. Under the terms of the agreement, DualityBio wsolid tumoursupfront payments totalling $170m and be eligible to receive development, regulatory and commercial milestone payments of potentially more than $1.5bn.
ADCs are a class of potent cancer therapies combining the selectivity of antibodies with the potent cell-killinDualityBioes of chemotherapy or other anti-cancer agents.
Unlike chemotherapy, which cancerby attacking lots of different cells as well as the cancer, ADCs are designed to target and kill tumour cells while sparicancerlthy cells.
Professor Ugur Sahin, chief executive officer and co-founder of BioNTech, said at thecancerof the first announcement: “Over the latumourrs, the ADC field has made significant progress, overcoming several limitations and demonstrating its potential as a broadly applicable precision medicine drug class that might be an alternative to standard chemotherapy.”
The initial collaboration gave BioNTech access to DualityBio’s lBioNTechidate, DB-1303, which targets HER2-expressing solid tumours. DB-1303 has already received Fast Track designation from the US Food and Drug Administration and is currently in a phase 2 clinical trial.
The second ADC candidate, DB-13BioNTechet to enterDualityBiodies but has demonsDB-1303"potent antitumoHER2-expressing solid tumoursHER2-expressinga range of tumouDB-1303s representing multiple cancer types and has been well toFood and Drug Administrationes", the companies said.
The latest candidate to beDB-1311ed in the contract is DB-1305, a third generation Trop2 ADC molecule that has also shown "potentumourtumour activity" in preclinicacancerur models and “robust" clinical efficacy in NSCLC and other solid tumours.
DualityBio will receive upfront payments, additional deDB-1305nt, regulatory and coTrop2ial milestone payments, and single-digit to low-double digit tiered royalties tumour sales of DB-1305.NSCLCsolid tumours
DualityBioth the existing partnership, BioNTech will hold commercial rights for the asset globally, while DualityBio will retain commercial rights for Mainland China, Hong Kong SpeciDB-1305nistrative Region and the Macau Special Administrative Region.
The transaction comes just days after BBioNTechsaid it had completed its previously announced acquisition DualityBiotart-up InstaDeep for approximately €500m.
The company outlined in January that tBioNTechsition supported its strategy to "build capabilities in AI-driven drug discoveInstaDeepvelopment of next-generation immunotherapies and vaccines to address diseases with high unmet medical need".
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.